CAR T-Cell Therapy Opportunity within Mantle Cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Mantle cell lymphoma (MCL) is a mature B-cell subtype of Non-Hodgkin lymphoma (NHL), characterized by translocation, primarily caused by an excessive expression of Cyclin D1. However, with the progress in our knowledge of the causes of MCL and available treatments for MCL, this cancer is still incurable. Poor prognostic indicators, such as age, male gender, rapid disease progression, significant nodal involvement, elevated serum lactate dehydrogenase level, increased expression of Ki-67, and TP53 mutation, are associated with an unfavorable outcome. The symptoms of MCL are similar to NHL, including lymphadenopathy, lymphocytosis, splenic enlargement, growth in Waldeyer's ring and tonsils, lymphomatous polyposis, and bone marrow infiltration. Interestingly, some patients may remain asymptomatic despite lymphocytosis. MCL can affect various extranodal sites, including the kidneys, soft tissues, skin, and the central nervous system (CNS). Non-nodal leukemic MCL often presents as asymptomatic indolent or 'smouldering' MCL. Advanced immunotherapy utilizing chimeric antigen receptor (CAR)-T cells shows promise in treating B-cell malignancies and MCL. Targeting B-cell antigens on the cell surface has proven effective in recurrent (R/R) MCL, as observed in other B-cell cancers. The USFDA has approved brexucabtagene autoleucel (Tecartus, KTE-X19), a novel CAR T-cell therapy, for use in MCL patients who have not responded to previous treatments or have experienced a relapse.

Thelansis’s “CAR T-Cell Therapy Opportunity within Mantle Cell Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential CAR T-Cell Therapy Opportunity within Mantle Cell Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of CAR T-Cell Therapy Opportunity within Mantle Cell Lymphoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

CAR T-Cell Therapy Opportunity within Mantle Cell Lymphoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: CAR T-Cell Therapy Opportunity within Mantle Cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033